

Michelle J Henderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8493602/publications.pdf>

Version: 2024-02-01

21
papers

1,625
citations

686830

13
h-index

752256

20
g-index

21
all docs

21
docs citations

21
times ranked

3337
citing authors

#	ARTICLE	IF	CITATIONS
1	ABC transporters in cancer: more than just drug efflux pumps. <i>Nature Reviews Cancer</i> , 2010, 10, 147-156.	12.8	920
2	ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1236-1251.	3.0	113
3	Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. <i>Blood</i> , 2007, 110, 632-639.	0.6	101
4	Direct and Coordinate Regulation of ATP-binding Cassette Transporter Genes by Myc Factors Generates Specific Transcription Signatures That Significantly Affect the Chemoresistance Phenotype of Cancer Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 19532-19543.	1.6	96
5	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. <i>Cancer Research</i> , 2017, 77, 971-981.	0.4	90
6	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). <i>Biochemical Pharmacology</i> , 2014, 91, 97-108.	2.0	53
7	Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant <i>MLL</i> -Rearranged Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 1395-1405.	3.2	43
8	OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. <i>Leukemia</i> , 2020, 34, 1828-1839.	3.3	37
9	Potent antileukemic activity of curaxin CBL0137 against <i>MLL</i> -rearranged leukemia. <i>International Journal of Cancer</i> , 2020, 146, 1902-1916.	2.3	30
10	Mechanism of relapse in pediatric acute lymphoblastic leukemia. <i>Cell Cycle</i> , 2008, 7, 1315-1320.	1.3	25
11	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 1524-1539.	3.3	20
12	A novel small molecule that kills a subset of <i>MLL</i> -rearranged leukemia cells by inducing mitochondrial dysfunction. <i>Oncogene</i> , 2019, 38, 3824-3842.	2.6	17
13	Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. <i>British Journal of Cancer</i> , 2021, 125, 55-64.	2.9	16
14	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression. <i>Cancer Research</i> , 2020, 80, 3706-3718.	0.4	15
15	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 4338-4352.	3.2	14
16	CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with <i>MLL</i> rearrangements. <i>Oncotarget</i> , 2016, 7, 46067-46087.	0.8	12
17	<i>ABCC4</i> / <i>MRP4</i> contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 2225-2238.	2.3	11
18	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. <i>British Journal of Cancer</i> , 2022, 126, 482-491.	2.9	7

#	ARTICLE	IF	CITATIONS
19	Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 779859.	1.3	3
20	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. <i>British Journal of Cancer</i> , 2022, 127, 908-915.	2.9	2
21	Analytical Quality Controls for ddPCR Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. <i>Clinical Chemistry</i> , 2021, 67, 1373-1383.	1.5	0